거림메디컬컨설팅

비상장계속사업자

Georim Medical Consulting Co.,Ltd.

박현

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

거림메디컬컨설팅

Business Reg. No. 4268801290 · CEO 박현

I.Investment Overview

Target거림메디컬컨설팅 (4268801290)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명거림메디컬컨설팅
영문명Georim Medical Consulting Co.,Ltd.
대표자박현
사업자등록번호4268801290
법인등록번호1801111197945
설립일2019.01.24

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW5.420238.520249.32025
영업이익100M KRW-22021-2.720220.820234.3202452025
순이익100M KRW-6.92021-9.52022-6.12023-2.320241.52025
Item20252024202320222021
자산총계160.3억원158.5억원156.8억원146.8억원132.1억원
부채총계157.3억원154억원156.6억원146.7억원140.6억원
자본총계3억원4.6억원2,548만원1,475만원-8.5억원
매출액9.3억원8.5억원5.4억원
영업이익5억원4.3억원8,160만원-2.7억원-2억원
순이익1.5억원-2.3억원-6.1억원-9.5억원-6.9억원

VI.Financial Ratios

FY2025 basis

53.61%

영업이익률

16.49%

순이익률

0.95%

ROA

50.27%

ROE

5,180.07%

부채비율

1.89%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

거림메디컬컨설팅 투심보고서 | Alpha Lenz